Compositions comprising cinnamaldehyde and zinc and methods of using such compositions

Patent metadata

Field	Value
Publication number	US-10092028-B2
Application number	US-201515327108-A
Country	US
Kind code	B2
Filing date	Jun 8, 2015
Priority date	Jul 18, 2014
Publication date	Oct 9, 2018
Grant date	Oct 9, 2018

Abstract

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to support weight managementor promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition comprising cinnamaldehydeis administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement. The composition can improve one or more of insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood or memory.

First claim

The invention is claimed as follows:

1. A method for improving a characteristic selected from the group consisting of insulin resistance, glucose tolerance, cognitive performance, cognition, mood, and memory, the method comprising administering to an individual in need thereof a composition comprising cinnamaldehyde and a compound comprising zinc, the compound is selected from the group consisting of zinc chloride, zinc sulfate, zinc lactate, zinc citrate, and mixtures thereof, and the composition is a food product in which the cinnamaldehyde:zinc ratio is 1:0.5 to 1:0.005 and the cinnamaldehyde is present at a flavoring concentration from 31.87 ppm to 100 ppm.

2. The method of claim 1 wherein the individual is selected from the group consisting of an infant born preterm, an infant experiencing intrauterine growth restriction, a pregnant woman suffering from gestational diabetes, a human suffering from insulin resistance, a human suffering from impaired glucose tolerance, and a human suffering from type II diabetes.

3. The method of claim 1 wherein the cinnamaldehyde is present in the composition in an amount that is safe and tolerable to ingest and, in combination with the zinc, effective to improve the characteristic selected from the group consisting of insulin resistance, glucose tolerance and a combination thereof.

4. The method of claim 1 wherein the composition comprises cinnamon essential oil extract that provides at least a portion of the cinnamaldehyde.

5. The method of claim 1 wherein at least a portion of the cinnamaldehyde is selected from the group consisting of isolated cinnamaldehyde and synthesized cinnamaldehyde.

6. The method of claim 1 wherein the composition is administered to the individual at least once a day for at least one week.

7. The method of claim 1 wherein the individual has a condition selected from the group consisting of cognitive decline, mild cognitive impairment, dementia, a mood disorder, memory loss, and combinations thereof.

8. The method of claim 1 , wherein the cinnamaldehyde:zinc ratio is 1:0.03.

Assignees

• Nestec Sa

Inventors

• Michlig Gonzalez Stephanie
• Meylan Merlini Jenny
• Camacho Susana
• Le Coutre Johannes

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title